Hemab Therapeutics/X
Sep 2, 2025, 12:50
New COO at Hemab Therapeutics: Anant Murthy to Advance Rare Blood Disorder Treatments
Hemab Therapeutics posted on X:
”Hemab is growing fast, and we’re thrilled to announce our new Chief Operating Officer, Anant Murthy, PhD.
In this new role, Dr. Murthy will lead the company’s global efforts in market access, launch, and commercialization, bringing Hemab’s promising pipeline of treatments for Glanzmann thrombasthenia, Von Willebrand disease, and other neglected blood clotting disorders with high unmet needs to patients worldwide.
Read more here.”
Stay updated with Hemostasis Today.
-
Jan 5, 2026, 15:33Mona Ahmed on Why Some Calcified Nodules Trigger ACS and Others Do Not
-
Jan 5, 2026, 14:17Abdul Mannan – VWF:RCo for Diagnosing von Willebrand Disease: That Test Might Be Failing Your Patients
-
Jan 5, 2026, 13:57Ewang Yemi: CAD is Real and Dangerous – Keep Your Heart Beating
-
Jan 5, 2026, 13:42Dr. Martha Boeckenfeld Shares VetiGel Creation Experiment: How A 17-Year-Old Mixed Algae in a Small Hidden Lab
-
Jan 5, 2026, 12:55Chokri Ben Lamine Explains Washed PRBCs!
-
Jan 5, 2026, 12:30ASH: Be Part of The Next Cohort of Hematology Quality Improvement Leaders
-
Jan 5, 2026, 09:59WFH Released New Evidence-Based Guidelines on AAV Gene Therapy for Hemophilia
-
Jan 5, 2026, 09:51Pete Stibbs: We Still Tend to Talk About VTE Like It’s a Plumbing Problem
-
Jan 5, 2026, 09:40Christopher Pittman on Treating Varicose Veins Before Knee or Hip Replacement